Pfizer Long-Term Investments 2010-2024 | PFE

Pfizer long-term investments from 2010 to 2024. Long-term investments can be defined as the aggregate value of debt and or equity investments with maturities or benefits lasting more than one year.
  • Pfizer long-term investments for the quarter ending September 30, 2024 were $11.148B, a 26.01% decline year-over-year.
  • Pfizer long-term investments for 2023 were $15.368B, a 1.98% increase from 2022.
  • Pfizer long-term investments for 2022 were $15.069B, a 30% decline from 2021.
  • Pfizer long-term investments for 2021 were $21.526B, a 6.24% increase from 2020.
Pfizer Annual Long-Term Investments
(Millions of US $)
2023 $15,368
2022 $15,069
2021 $21,526
2020 $20,262
2019 $20,147
2018 $2,767
2017 $7,015
2016 $7,116
2015 $15,999
2014 $17,518
2013 $16,406
2012 $14,149
2011 $9,814
2010 $9,747
2009 $13,122
Pfizer Quarterly Long-Term Investments
(Millions of US $)
2024-06-30 $11,148
2024-03-31 $11,613
2023-12-31 $15,368
2023-09-30 $14,239
2023-06-30 $15,066
2023-03-31 $14,743
2022-12-31 $15,069
2022-09-30 $13,888
2022-06-30 $18,962
2022-03-31 $20,737
2021-12-31 $21,526
2021-09-30 $21,597
2021-06-30 $20,942
2021-03-31 $20,228
2020-12-31 $20,262
2020-09-30 $19,008
2020-06-30 $18,720
2020-03-31 $18,220
2019-12-31 $20,147
2019-09-30 $18,722
2019-06-30 $2,905
2019-03-31 $2,859
2018-12-31 $2,767
2018-09-30 $6,444
2018-06-30 $6,595
2018-03-31 $6,945
2017-12-31 $7,015
2017-09-30 $7,311
2017-06-30 $7,008
2017-03-31 $7,346
2016-12-31 $7,116
2016-09-30 $9,507
2016-06-30 $13,124
2016-03-31 $14,146
2015-12-31 $15,999
2015-09-30 $16,233
2015-06-30 $17,650
2015-03-31 $18,289
2014-12-31 $17,518
2014-09-30 $18,451
2014-06-30 $17,168
2014-03-31 $15,822
2013-12-31 $16,406
2013-09-30 $15,731
2013-06-30 $16,107
2013-03-31 $15,392
2012-12-31 $14,149
2012-09-30 $13,429
2012-06-30 $10,548
2012-03-31 $10,632
2011-12-31 $9,814
2011-09-30 $9,468
2011-06-30 $10,207
2011-03-31 $9,811
2010-12-31 $9,747
2010-09-30 $10,344
2010-06-30 $10,524
2010-03-31 $12,081
2009-12-31 $13,122
2009-09-30 $12,166
2009-06-30 $12,576
2009-03-31 $13,536
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $151.422B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $789.394B 81.76
Novo Nordisk (NVO) Denmark $481.063B 34.69
Johnson & Johnson (JNJ) United States $374.313B 15.18
AbbVie (ABBV) United States $352.544B 18.56
Merck (MRK) United States $260.350B 17.30
Novartis AG (NVS) Switzerland $217.584B 14.46
AstraZeneca (AZN) United Kingdom $199.957B 17.81
Sanofi (SNY) $130.241B 11.80
Innoviva (INVA) United States $1.263B 10.51